SELECT-AXIS 2 trial demonstrated efficacy and safety of upadacitinib in treatment of non-radiographic axSpA. ASAS40 at week 14 (45% vs. 23% placebo). No MACE, VTEs, IBD, death. @RheumNow #EULAR2022 ABST#OP0016 https://t.co/vyky0JJJjS